Fast-Track Given to Hepatitis C Drug ACH-1625
Share
Follow Us
The Editors at Hepatitis Central
January 9, 2012
Likely due to its convenient dosing, safety and tolerability, Achillion’s ACH-1625 has been awarded fast-track status by FDA.
Achillion hepatitis drug gets faster FDA review
January 4, 2012
(AP) NEW HAVEN, Conn. — A chronic hepatitis c treatment being developed by from Achillion Pharmaceuticals received fast track designation, allowing for a quicker review by regulators.
Achillion said Wednesday the treatment, labeled ACH-1625, is in mid-stage clinical testing. The designation allows drug developers to submit their applications to the Food and Drug Administration piece by piece instead of having to file all the paperwork at once.
It also allows for more frequent interaction with regulators and a possible priority review.
Continue reading this entire article:
http://www.cbsnews.com/8301-505245_162-57351972/achillion-hepatitis-drug-gets-faster-fda-review/
